|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
A biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancer
|
1R37CA222294-01A1
|
$366,000
|
ABAZEED, MOHAMED
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Novel platform linking cancer-specific glycosylation with cell signaling outcomes
|
1R21CA229044-01
|
$225,250
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
3UM1CA186704-04S1
|
$170,500
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
University of North Carolina Womens Interagency HIV Study UNC WIHS
|
3U01AI103390-05S1
|
$60,652
|
ADIMORA, ADAORA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
|
1R01CA236615-01
|
$392,764
|
ADUSUMILLI, PRASAD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Leveraging polyamine metabolic stress as a novel therapy for prostate cancer
|
4K00CA212455-03
|
$69,749
|
AFFRONTI, HAYLEY
|
UNIVERSITY OF PENNSYLVANIA
|
|
Genetics of Graft-versus-Host Disease
|
1R01CA231141-01
|
$265,229
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-05
|
$382,616
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Policy- and Provider-Level Determinants of Human Papillomavirus Vaccination Disparities Among Young U.S. Women
|
1K01CA234226-01
|
$158,403
|
AGENOR, MADINA
|
TUFTS UNIVERSITY MEDFORD
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems
|
1R01CA227136-01A1
|
$454,956
|
AGHI, MANISH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S1
|
$54,859
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S2
|
$188,884
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
Dr. Keiko Akagi, A Bioinformatics Specialist in Cancer Genomics Research at OSU Comprehensive Cancer Center
|
5R50CA211533-03
|
$122,475
|
AKAGI, KEIKO
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Metabolic Syndrome and Epigenetic Markers of Breast Cancer in Nigerian Women
|
5K01TW010271-03
|
$134,531
|
AKINYEMIJU, TOMI
|
UNIVERSITY OF KENTUCKY
|
|
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade
|
1R43CA228721-01
|
$299,607
|
AKPORIAYE, EMMANUEL
|
VEANA THERAPEUTICS, LLC
|
|
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
|
1P01CA217805-01A1
|
$2,105,511
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Chemically produced neural progenitors as a delivery vehicle for anti-glioma therapy
|
1R43CA221490-01A1
|
$300,000
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer
|
1R44CA233140-01
|
$299,412
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
|
7R01CA182076-05
|
$339,622
|
ALLEN, PETER
|
DUKE UNIVERSITY
|
|
Oncohistones: Role of Histone H3 Mutations in the Oncogenesis of Pediatric Cancers
|
5P01CA196539-04
|
$1,855,117
|
ALLIS, CHARLES
|
ROCKEFELLER UNIVERSITY
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Oncogenic Disruption of the Circadian Metabolic Cycle in Cancer
|
4R00CA204593-03
|
$249,000
|
ALTMAN, BRIAN
|
UNIVERSITY OF ROCHESTER
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
3R01CA208042-03S1
|
$223,893
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma
|
1R01CA222931-01A1
|
$370,575
|
AMENGUAL, JENNIFER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies
|
3U19CA203654-02S1
|
$147,830
|
AMOS, CHRISTOPHER
|
BAYLOR COLLEGE OF MEDICINE
|
|
Functional Contribution of Metabolic Complex to Cancer Cell Metabolism
|
1R03CA219609-01A1
|
$72,194
|
AN, SONGON
|
UNIVERSITY OF MARYLAND BALT CO CAMPUS
|
|
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
|
3R01AR070234-04S1
|
$55,691
|
ANANDASABAPATHY, NIROSHANA
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
Developing Human Induced Pluripotent Stem Cell Precision Oncology Models
|
1R50CA233164-01
|
$155,981
|
ANASTASAKI, CORINA
|
WASHINGTON UNIVERSITY
|
|
Womens Interagency HIV Study (WIHS-V)
|
3U01AI035004-25S1
|
$144,370
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Steroid hormone regulation of immune responses
|
1R01CA229400-01
|
$384,018
|
ANDERSON, ANA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Resource stratified phased implementation frameworks to improve breast healthcare
|
1R13CA224776-01A1
|
$50,000
|
ANDERSON, BENJAMIN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
|
1U01CA232382-01
|
$688,043
|
ANDERSON, ALEXANDER
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Disruption of T cell tolerance in type 1 diabetes
|
3P01AI118688-03S1
|
$52,804
|
ANDERSON, MARK
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Womens Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S3
|
$175,562
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Unmasking targetable dependencies in cancer with intrinsic or acquired resistance to anti-cancer therapies
|
5F99CA222728-02
|
$35,610
|
ANDERSON, GRACE
|
DUKE UNIVERSITY
|
|
Predictive signatures in breast cancer using multiplexed ion beam imaging
|
5DP5OD019822-05
|
$401,249
|
ANGELO, ROBERT
|
STANFORD UNIVERSITY
|
|
Cancer Metabolism Training Program
|
1T32CA221709-01A1
|
$201,444
|
ANN, DAVID
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients
|
3R01CA201124-03S1
|
$189,200
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Multiscale proteomics studies of DNA repair and genomic stability
|
1R50CA233182-01
|
$162,365
|
APARICIO CASADO, TOMAS
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|